Skip to main navigation Skip to search Skip to main content

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

Frank P. Vendetti, Alan Lau, Sandra Schamus, Thomas P. Conrads, Mark J. O'Connor, Christopher J. Bakkenist*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

212 Scopus citations

Fingerprint

Dive into the research topics of 'The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology